Covid-19 Innovation Challenges by Innoget

SARS-CoV-2 Helicase Targeted Library

Posted by Covid-19 Innovation Challenges by InnogetVery responsive · Innovative Products and Technologies · United Kingdom

Send your request

Summary of the technology

The offer SARS-CoV-2 Helicase (NSP13) Targeted Library, which contain 1170 compounds with predicted activity against this vital protein. The overall procedure included accurate flexible docking of Drug-like Green Collection into helicase active site.

Covid-19 Innovation Challenges by Innoget

Description of the technology

We offer a target library of SARS-CoV-2 Helicase (NSP13), which contains 1170 compounds with predicted activity on helicase SARS-CoV-2 (non-structural protein 13, NSP13), which is important for coronavirus replication. It separates double-stranded RNA (dsRNA). The identification of small molecules for which the replication apparatus is a target has shown the highest potential for the detection of antiviral drugs.

The library was developed based on virtual screening receptors using a homologous model of SARS-CoV-2 NSP13. Final selection of compounds was performed based on key structural determinants of the enzymatic active site for ligand binding, scoring, and intermolecular hydrogen bonds with key amino acid residues of the active site.

Technology Owner

Covid-19 Innovation Challenges by Innoget

Innovation Intermediary

Related keywords

  • Applications for Health
  • Biological Sciences
  • Medicine, Human Health
  • Biostatistics, Epidemiology
  • Diagnostics, Diagnosis
  • Medical Research
  • Human vaccines
  • Emergency Medicine Technology
  • Genetic Engineering Technology
  • Infectious Diseases
  • Medical/health
  • Genetic Engineering / Molecular Biology
  • Genetic Engineering Market
  • Medical Health related
  • Diagnostic
  • Diagnostic services
  • Covid-19
  • compounds
  • coronavirus
  • sars-cov-2

About Covid-19 Innovation Challenges by Innoget

Innovation Intermediary from United Kingdom

Ahead of the current Coronavirus outbreak, Innoget is fully committed to contributing to mobilizing scientific and expert communities to find a real solution to the Covid-19 pandemic. Therefore, we're supporting worldwide calls and programs that could help in any aspects of the coronavirus crisis.

Is your organization promoting or looking for innovation or research initiatives to mitigate the Covid-19 outbreak? Email us at covid19@innoget.com to list them.

Channeled through Innoget's online open innovation network, initiatives in the health, virology, medicine, or novel technologies applied to human health, among others, are listed and disseminated to Innoget members -ranging from hospitals, research institutes, scientists, businesses, and public administrations- and innovation partners worldwide.

Similar Technology Offers

New method for the diagnosis of diseases caused by helminths

Cystic Echinococcosis, also known as hydatid disease (Hydatidosis), is a parasitic disease caused by the tapeworms of genus Echinococcus. Hydatidosis is globally distributed and found in every continent except Antarctica. Endemic areas are parts of Argentina, Peru, East Africa, Central Asia and China. The infection to humans occur through the ingestion of parasite eggs in contaminated water, food, soil or through direct contact with animal hosts such as dogs and sheep. Human infection with E. granulosus leads to the development of one or more hydatid cysts located most often in the liver and lungs, and less frequently in the bones, kidneys, spleen, muscles, central nervous system and eyes. The asymptomatic incubation period of the disease can last many years until hydatid cysts grow to an extent that triggers clinical signs. The diagnosis is done through ultrasonography imaging, which is usually complemented or validated by computed tomography and/or magnetic resonance imaging scans. Cysts can be incidentally discovered by radiography. Specific antibodies are detected by different serological tests and can support the diagnosis. Biopsies and ultrasound-guided punctures may also be performed for differential diagnosis of cysts from tumours and abscesses. In this invention, a new system for non-invasive, early, fast and easy to use diagnosis test for Hydatidosis from exhaled breath analysis has been developed.

New method for the diagnosis of diseases caused by helminths
  • +2 weeks
  • Hide post

PSA purification and concentration from urine samples for non-invasive early stage diagnosis of prostate cancer

New method for the pretreatment of human urine sam-ples, comprising the simultaneous extraction, concentration and purification of the prostate-specific antigen (PSA), a prostate cancer biomarker. In this technology, aqueous biphasic systems composed of ionic liquids and salts are used. These systems allow the selective extraction of PSA and to obtain high con-centration/enrichment factors, enabling the quantification of PSA using less sophisticated, cheaper and more affordable equipment.

PSA purification and concentration from urine samples for non-invasive early stage diagnosis of prostate cancer
  • +6 months
  • Hide post

Novel Naturally Occurring Compounds for Treating Respiratory Infections

Cannabis project Preliminary data on CF Derivatives of cannabinoids have an antimicrobial and anti biofilm effect on pseudomonas and candida which are major ethological pathogenic factors in CF Project ID : 6-2019-6720

  • +6 months
  • Hide post

Modulating compounds of KChIP2 and its use for the treatment of cardiovascular

ppaatthhoollooggiieess CSIC and UAM have developed compounds that positively modulate protein-protein interactions that involve KChIP2 protein. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement An offer for Patent Licensing

Modulating compounds of KChIP2 and its use for the treatment of cardiovascular
  • +6 months
  • Hide post

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors
  • +6 months
  • Hide post

View other related tech offers

Submit your request
Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Other users also viewed

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion InhibitorsExpertise in molecular biology either experimentally or computationallyExpertise in molecular biology either experimentally or computationallyCOVID-19 Rapid Diagnostic KitCOVID-19 Rapid Diagnostic Kit